Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 21, 2019 22:50:33 GMT -5
$5MM which is in Escrow. IMO MNKD is working on a total RECAP which will payoff DF and everyone else and add more capital w/ much better terms and a due date of 2025. I'm expecting a rate of 5.25%. I seriously doubt we get 5.25%. I would expect a lot near 9.5% or higher. Mannkind is a micro-cap - that's not a compelling loan candidate. Well then explain why SENS just did a convertible deal at 5.25%. They are a micro cap with small revenues and debt. Let's see what MNKD can do. I also believe they will have several offers and this time will not be forced into a bad deal.
|
|
|
Post by mnkdfann on Jul 22, 2019 0:09:28 GMT -5
I seriously doubt we get 5.25%. I would expect a lot near 9.5% or higher. Mannkind is a micro-cap - that's not a compelling loan candidate. Well then explain why SENS just did a convertible deal at 5.25%. They are a micro cap with small revenues and debt. Let's see what MNKD can do. I also believe they will have several offers and this time will not be forced into a bad deal. Several people already explained it: mnkd.proboards.com/post/184445"SENS had around a 100 million cash, about 40 million debt , and Roche as a partner. I don't believe Mannkind's situation is quite analogous." mnkd.proboards.com/post/184449"SENS product has not been on the market for five years. Also their product is not selling way below expectations and has a large percentage of doctors who want no business with Afrezza."
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 22, 2019 6:30:45 GMT -5
Well then explain why SENS just did a convertible deal at 5.25%. They are a micro cap with small revenues and debt. Let's see what MNKD can do. I also believe they will have several offers and this time will not be forced into a bad deal. Several people already explained it: mnkd.proboards.com/post/184445"SENS had around a 100 million cash, about 40 million debt , and Roche as a partner. I don't believe Mannkind's situation is quite analogous." mnkd.proboards.com/post/184449"SENS product has not been on the market for five years. Also their product is not selling way below expectations and has a large percentage of doctors who want no business with Afrezza." The glass is HALF FULL.....NOT HALF EMPTY
|
|
|
Post by agedhippie on Jul 22, 2019 9:18:24 GMT -5
Several people already explained it: mnkd.proboards.com/post/184445"SENS had around a 100 million cash, about 40 million debt , and Roche as a partner. I don't believe Mannkind's situation is quite analogous." mnkd.proboards.com/post/184449"SENS product has not been on the market for five years. Also their product is not selling way below expectations and has a large percentage of doctors who want no business with Afrezza." The glass is HALF FULL.....NOT HALF EMPTY That's as maybe for MNKD, but the SENS glass is FULL.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 22, 2019 10:00:12 GMT -5
The glass is HALF FULL.....NOT HALF EMPTY That's as maybe for MNKD, but the SENS glass is FULL. SENS is in the same boat as MNKD - Stiff competition and will have to raise more money eventually.
|
|
|
Post by agedhippie on Jul 22, 2019 10:32:46 GMT -5
That's as maybe for MNKD, but the SENS glass is FULL. SENS is in the same boat as MNKD - Stiff competition and will have to raise more money eventually. The difference is that the insulin market is mature, the CGM market isn't. That makes competition far easier as there is still a large unmet market (90%) for CGMs. That is reflected in a lower risk which in turn is reflected in the rate lenders charge.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 23, 2019 7:29:16 GMT -5
SENS is in the same boat as MNKD - Stiff competition and will have to raise more money eventually. The difference is that the insulin market is mature, the CGM market isn't. That makes competition far easier as there is still a large unmet market (90%) for CGMs. That is reflected in a lower risk which in turn is reflected in the rate lenders charge. You apparently have not worked in the corporate debt market.
|
|
|
Post by agedhippie on Jul 23, 2019 8:10:05 GMT -5
The difference is that the insulin market is mature, the CGM market isn't. That makes competition far easier as there is still a large unmet market (90%) for CGMs. That is reflected in a lower risk which in turn is reflected in the rate lenders charge. You apparently have not worked in the corporate debt market. Only peripherally on the buy side. A mature market is very desirable if you are an incumbent with stable market share from a lender's point of view. A new market with good supporting data (the market really exists) is better for newcomers. The CGM market is new, supported, and under-served so it looks like a reasonable risk.
|
|
|
Post by sayhey24 on Jul 23, 2019 8:19:28 GMT -5
You apparently have not worked in the corporate debt market. Only peripherally on the buy side. A mature market is very desirable if you are an incumbent with stable market share from a lender's point of view. A new market with good supporting data (the market really exists) is better for newcomers. The CGM market is new, supported, and under-served so it looks like a reasonable risk. Aged - if you think the CGM market is immature the TIR market is just starting. I am not sure what products but afrezza currently play in this market.
|
|
|
Post by mnholdem on Jul 23, 2019 8:28:24 GMT -5
If only mgt were to know how to play...
|
|
|
Post by agedhippie on Jul 23, 2019 8:32:40 GMT -5
Only peripherally on the buy side. A mature market is very desirable if you are an incumbent with stable market share from a lender's point of view. A new market with good supporting data (the market really exists) is better for newcomers. The CGM market is new, supported, and under-served so it looks like a reasonable risk. Aged - if you think the CGM market is immature the TIR market is just starting. I am not sure what products but afrezza currently play in this market. TIR is not a market. There is no large scale study that proves Afrezza hits TIR targets (yes, I think it does hit them, but you need trial data). Right now pumps like the 670G can say that they exceed the TIR targets (72%) and the 780G to be released next April hits 80% TIR. The Tandem with Control-IQ hits 71%. Those are all large scale trials. The message this sends to the medical world is no change - pumps are just fine. Now there is the Type 2 market where getting a pump is just a pipe-dream, but again Afrezza falls at the lack of trial data. The TIR standard is not quite here yet (they need a really big trial to prove it), but the pump manufacturers are going to be pushing TIR like crazy.
|
|
|
Post by sayhey24 on Jul 23, 2019 8:56:39 GMT -5
Aged - lots of double speak. The reality is no pump can mimic the afrezza time action profile. Subq is subq whether its with a pump or a needle. The STAT showed 100% TIR with afrezza during the afrezza use period 9am to 9pm. You can't do much better than that.
If you are a T1 and want 2am control and are on MDI Dr. Kendal said increase the basal. If they had done that on the STAT you probably If you are pumping, no action needed. If you are a T2 with decent beta cell activity, no worries you pancreas will take care of 2am TIR.
As I said the more immature market between CGM and TIR is clearly TIR. The only product that I know engineered to produce the time/action profile of a healthy pancreas to achieve TIR is afrezza. Subq pumped or shot can never provide the post prandial profile of afrezza for tight TIR control.
|
|
|
Post by shawnonafrezza on Jul 23, 2019 9:48:34 GMT -5
"during the afrezza use period 9am to 9pm".
So it reality it could be 50% TIR. Just playing with numbers and only counting the waking moment of a PWD is quite misleading which is why I know myself and others don't care about STAT TIR. True that subq is only as fast as subq is but Afrezza is also only as fast as the PWD using it. On the freeway and your G6 goes off? You can't do anything. Fortunately it's fast enough that when you do correct it won't be long to get back in range but that is going go hurt that 100%.
"Subq pumped or shot can never provide the post prandial profile of afrezza for tight TIR control."
Agree 100%. But what is good enough? IMO (and as a patient who's used God knows how many techniques) we don't need perfect, we need good enough. If a 10-15 pre bolus is needed but that pre bolus is also predicted for you is it good enough? I won't be the one to answer that but it is something I think often gets way undervalued here especially with the likes of beta bionics (and uril) on the way who will be able to aggressively administer insulin.
|
|
|
Post by mnholdem on Jul 23, 2019 13:36:00 GMT -5
Perhaps you haven’t been around long enough to remember the video of a guy taking his Afrezza while riding his motorcycle?
An Afrezza inhaler is way different than your pen.
|
|
|
Post by brentie on Jul 23, 2019 15:21:00 GMT -5
Perhaps you haven’t been around long enough to remember the video of a guy taking his Afrezza while riding his motorcycle? An Afrezza inhaler is way different than your pen. Get your motor running...
|
|